Canada's Edesa Biotech Q1 net loss widens

Edesa Biotech

13/02/2026 21:28

Corrects third bullet of Outlook to say  Edesa is continuing to evaluate, not planning, opportunities such as establishing investigational sites across multiple jurisdictions

Overview

Canada biopharma firm's Q1 net loss widened to $2.2 mln, driven by higher expenses

Operating expenses rose to $2.3 mln due to increased R&D and admin costs

Outlook

Company anticipates recruitment for vitiligo study to begin midyear 2026

Edesa exploring accelerated commercialization pathways for paridiprubart

Company continuing to evaluate opportunities, such as establishing investigational sites across multiple jurisdictions

Result Drivers

VITILIGO STUDY PREPARATION - Increased R&D expenses due to manufacturing and preparations for Phase 2 study of EB06 in vitiligo patients

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.28
Q1 Net Income
-$2.2 mln
Q1 Operating Expenses
$2.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 804.5% above its February 12 closing price of $1.00

Press Release: ID:nGNX8QP1VK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)